4/15
04:34 pm
oric
ORIC Pharmaceuticals Announces First Patients Dosed Across Three Expansion Cohorts in Phase 1b Trial of ORIC-114 in Patients with Mutated NSCLC [Yahoo! Finance]
Low
Report
ORIC Pharmaceuticals Announces First Patients Dosed Across Three Expansion Cohorts in Phase 1b Trial of ORIC-114 in Patients with Mutated NSCLC [Yahoo! Finance]
4/15
04:15 pm
oric
ORIC Pharmaceuticals Announces First Patients Dosed Across Three Expansion Cohorts in Phase 1b Trial of ORIC-114 in Patients with Mutated NSCLC
Low
Report
ORIC Pharmaceuticals Announces First Patients Dosed Across Three Expansion Cohorts in Phase 1b Trial of ORIC-114 in Patients with Mutated NSCLC
4/8
08:14 am
oric
ORIC Pharmaceuticals Presents Preclinical Data on Two Programs at the 2024 American Association for Cancer Research (AACR) Annual Meeting [Yahoo! Finance]
Medium
Report
ORIC Pharmaceuticals Presents Preclinical Data on Two Programs at the 2024 American Association for Cancer Research (AACR) Annual Meeting [Yahoo! Finance]
4/8
08:00 am
oric
ORIC Pharmaceuticals Presents Preclinical Data on Two Programs at the 2024 American Association for Cancer Research (AACR) Annual Meeting
Medium
Report
ORIC Pharmaceuticals Presents Preclinical Data on Two Programs at the 2024 American Association for Cancer Research (AACR) Annual Meeting
4/5
04:30 pm
oric
ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
Low
Report
ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
4/4
04:33 pm
oric
ORIC Pharmaceuticals to Participate in Upcoming Investor Conferences [Yahoo! Finance]
Low
Report
ORIC Pharmaceuticals to Participate in Upcoming Investor Conferences [Yahoo! Finance]
4/4
04:30 pm
oric
ORIC Pharmaceuticals to Participate in Upcoming Investor Conferences
Low
Report
ORIC Pharmaceuticals to Participate in Upcoming Investor Conferences
3/29
05:40 am
oric
ORIC Pharmaceuticals: Rally Seems Overdone [Seeking Alpha]
Medium
Report
ORIC Pharmaceuticals: Rally Seems Overdone [Seeking Alpha]
3/27
10:56 am
oric
ORIC Pharmaceuticals, Inc. (NASDAQ: ORIC) had its price target lowered by analysts at JPMorgan Chase & Co. from $19.00 to $18.00. They now have an "overweight" rating on the stock.
Low
Report
ORIC Pharmaceuticals, Inc. (NASDAQ: ORIC) had its price target lowered by analysts at JPMorgan Chase & Co. from $19.00 to $18.00. They now have an "overweight" rating on the stock.
3/21
08:06 am
oric
ORIC Pharmaceuticals, Inc. (NASDAQ: ORIC) had its price target raised by analysts at HC Wainwright from $15.00 to $21.00. They now have a "buy" rating on the stock.
Low
Report
ORIC Pharmaceuticals, Inc. (NASDAQ: ORIC) had its price target raised by analysts at HC Wainwright from $15.00 to $21.00. They now have a "buy" rating on the stock.
3/13
08:52 am
oric
ORIC Pharmaceuticals: Mid-2024 Prostate Cancer Program Update Could Lead To Gains [Seeking Alpha]
Low
Report
ORIC Pharmaceuticals: Mid-2024 Prostate Cancer Program Update Could Lead To Gains [Seeking Alpha]
3/11
04:27 pm
oric
ORIC Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Operational Updates [Yahoo! Finance]
Low
Report
ORIC Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Operational Updates [Yahoo! Finance]
3/11
04:05 pm
oric
ORIC Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Operational Updates
Medium
Report
ORIC Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Operational Updates
3/8
05:12 pm
oric
ORIC Pharmaceuticals Inc CEO Jacob Chacko Sells 40,000 Shares [Yahoo! Finance]
Low
Report
ORIC Pharmaceuticals Inc CEO Jacob Chacko Sells 40,000 Shares [Yahoo! Finance]
3/6
04:30 pm
oric
ORIC Pharmaceuticals to Present at the Leerink Partners Global Biopharma Conference
Low
Report
ORIC Pharmaceuticals to Present at the Leerink Partners Global Biopharma Conference
3/5
04:43 pm
oric
ORIC Pharmaceuticals Announces Multiple Presentations at the 2024 American Association for Cancer Research (AACR) Annual Meeting [Yahoo! Finance]
Medium
Report
ORIC Pharmaceuticals Announces Multiple Presentations at the 2024 American Association for Cancer Research (AACR) Annual Meeting [Yahoo! Finance]
3/5
04:30 pm
oric
ORIC Pharmaceuticals Announces Multiple Presentations at the 2024 American Association for Cancer Research (AACR) Annual Meeting
Medium
Report
ORIC Pharmaceuticals Announces Multiple Presentations at the 2024 American Association for Cancer Research (AACR) Annual Meeting
3/1
04:30 pm
oric
ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
Medium
Report
ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
3/1
09:03 am
oric
ORIC Pharmaceuticals, Inc. (NASDAQ: ORIC) had its price target raised by analysts at Wedbush from $12.00 to $20.00. They now have an "outperform" rating on the stock.
High
Report
ORIC Pharmaceuticals, Inc. (NASDAQ: ORIC) had its price target raised by analysts at Wedbush from $12.00 to $20.00. They now have an "outperform" rating on the stock.
2/23
07:31 am
oric
ORIC Pharmaceuticals, Inc. (NASDAQ: ORIC) is now covered by analysts at Cantor Fitzgerald. They set an "overweight" rating on the stock.
Medium
Report
ORIC Pharmaceuticals, Inc. (NASDAQ: ORIC) is now covered by analysts at Cantor Fitzgerald. They set an "overweight" rating on the stock.
2/14
04:30 pm
oric
ORIC Pharmaceuticals to Participate in the Citi 2024 Virtual Oncology Leadership Summit
Low
Report
ORIC Pharmaceuticals to Participate in the Citi 2024 Virtual Oncology Leadership Summit
2/9
02:34 am
oric
ORIC Pharmaceuticals CEO Jacob Chacko Sells 40,000 Shares [Yahoo! Finance]
Medium
Report
ORIC Pharmaceuticals CEO Jacob Chacko Sells 40,000 Shares [Yahoo! Finance]
2/7
10:10 am
oric
TuHURA Biosciences, Inc. Appoints Dennis Yamashita, Ph.D., as Chief Scientific Officer and Head of Discovery Research and Early Development [Yahoo! Finance]
Low
Report
TuHURA Biosciences, Inc. Appoints Dennis Yamashita, Ph.D., as Chief Scientific Officer and Head of Discovery Research and Early Development [Yahoo! Finance]
2/2
04:30 pm
oric
ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
Low
Report
ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
2/1
03:13 pm
oric
Andreas Halvorsen's Viking Global Investors LP Acquires New Stake in ORIC Pharmaceuticals Inc [Yahoo! Finance]
Low
Report
Andreas Halvorsen's Viking Global Investors LP Acquires New Stake in ORIC Pharmaceuticals Inc [Yahoo! Finance]